These findings suggest that AS-IV disrupts the core pathological processes of EMT and fibrosis progression by modulating TGF-β1 and E-cadherin-associated signaling molecules, effectively alleviating the pathological progression of PF. This evidence concerns the gene TGFB1 and pemphigus foliaceus.